<DOC>
	<DOC>NCT01261741</DOC>
	<brief_summary>In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.</brief_summary>
	<brief_title>Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Memory Disorders</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Subjective worsening of memory, concentration or attention problems for longer than 6 months Subject can confirm that a relative or friend has noticed the memory, concentration or attention problems of the subject Experience of the memory, concentration or attention problems at least four times per week Significant neurological disease or major psychiatric disorder (e.g. diagnosis of psychosis or dementia) Significant systemic illness, such as cancer, heart or kidney failure, uncontrolled diabetes History of stroke or seizure, or myocardial infarction within the last year (e.g. by inclusion questionnaire, physician interview)</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>